<DOC>
	<DOCNO>NCT00408681</DOCNO>
	<brief_summary>RATIONALE : Lithium carbonate may effective treatment intestinal graft-versus-host disease cause donor stem cell transplant . PURPOSE : This clinical trial study lithium carbonate treat patient acute intestinal graft-versus-host-disease donor stem cell transplant .</brief_summary>
	<brief_title>Lithium Carbonate Treating Patients With Acute Intestinal Graft-Versus-Host-Disease ( GVHD ) After Donor Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate effect lithium functional mucosal anatomic recovery small large bowel patient acute GVHD . II . Functional recovery evaluate accord change clinical manifestation gastrointestinal GVHD . III . Mucosal anatomic recovery evaluate review result clinically indicate endoscopic evaluation . SECONDARY OBJECTIVES : I . To assess tolerability lithium administration allogeneic hematopoietic cell transplant recipient . OUTLINE : Patients receive oral lithium carbonate twice daily . Treatment continue 8 week absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Germinoma</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Embryonal</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Leukemia , Neutrophilic , Chronic</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Trophoblastic Neoplasms</mesh_term>
	<mesh_term>Gestational Trophoblastic Disease</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Patient diagnosis severe intestinal GVHD improving time initial treatment glucocorticoid least 7 day eligible enrollment ; measure indicate severity GVHD include : ) persistent diarrhea average daily stool volume &gt; 500 mL per day ; b ) persistent hemorrhage detectable visual inspection stool Patients denude mucosa cause GVHD eligible enrollment , regardless prior treatment acute GVHD ; denude mucosa define loss ( i.e. , erosion slough ) epithelium : ) least onethird surface area 30 cm colonic segment ( i.e. , rectosigmoid , descend transverse colon ) ; b ) least one fifth surface area second portion duodenum , estimate endoscopic evaluation ; denude mucosa must document image duodenum colon histologic evaluation colon All subject must provide write informed consent use form approve Fred Hutchinson Cancer Research Center ( FHCRC ) Institutional Review Board ( IRB ) Significant renal dysfunction ( estimate creatinine clearance &lt; 30 mL/min ) Persistent recurrent malignancy Secondary malignancy Patients autologous syngeneic marrow transplantation Presence cause intestinal symptom ulceration GVHD Patients psychological , familial , sociological geographical condition potentially hamper compliance study protocol exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>